Overview

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

Status:
NOT_YET_RECRUITING

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Children's Medical Center

Treatments:

Olanzapine